Previous 10 | Next 10 |
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and C...
CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and c...
uniQure has submitted data to the FDA that suggest that etranacogene dezaparvovec (AMT-061) is highly unlikely to be the cause of liver cancer in a patient in the pivotal trial. FTC review of the transaction with CSL Behring is ongoing and is projected to close during the second quart...
Shares of Wave Life Sciences (NASDAQ: WVE) are down 29% at 1:29 p.m. EDT after the company announced that WVE-120102 and WVE-120101, two of its drugs to treat Huntington's disease, failed to show an effect in early stage clinical trials. Huntington's disease is caused by differe...
Gainers: VirTra (VTSI) +83%.Color Star Technology (CSCW) +39%.Performant Financial (PFMT) +36%.VivoPower International (VVPR) +32%.Moxian (MOXC) +26%.Mannatech (MTEX) +23%.Novan (NOVN) +21%.Canaan (CAN) +20%.Lizhi (LIZI) +17%.17 Education & Technology (YQ) +17%.Losers: Elit...
Gainers: Novan (NOVN) +17%, ShockWave Medical (SWAV) +17%, Orphazyme (ORPH) +13%, Moleculin Biotech (MBRX) +14%, Annovis Bio (ANVS) +8%.Losers: Wave Life Sciences (WVE) -30%, Trxade (MEDS) -27%, Universe Pharmaceuticals (UPC)...
Gainers: [[SEAC]] +30.3%. [[ABCL]] +13.7%. [[VSTM]] +9.7%. [[GIII]] +9.5%. [[RRR]] +8.8%.Losers: [[WVE]] -24.8%. [[SCPH]] -15.4%. [[PCVX]] -12%. [[UPC]] -9.5%. [[TDUP]] -6%. For further details see: VSTM, WVE, ABCL and SCPH among after-hours movers
Wave Life Sciences (WVE) has lost more than a quarter after announcing a halt to the clinical development of WVE-120102 and WVE-120101 in Huntington’s disease (“HD”).“mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120...
mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120101 No observed change in wtHTT and NfL during trials Advancing Phase 1b/2a trial for WVE-003 (SNP3) program in HD; WVE-003 uses new PN backbone chemistry modifications, which...
Ionis Pharmaceuticals ([[IONS]] -22.5%) has lost almost a fifth after announcing that the partner Roche Holding ([[RHHBY]] -3.3%) has discontinued the dosing in the Phase III GENERATION HD1 study for Tominersen in manifest Huntington's disease (“HD”).An investigational...
News, Short Squeeze, Breakout and More Instantly...
Wave Life Sciences Ltd. Company Name:
WVE Stock Symbol:
NASDAQ Market:
Wave Life Sciences Ltd. Website:
2024-07-17 15:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation of wild-type huntingtin (wtHTT) protein, and generally safe and well-tolerated profile achieved in 30 mg multidose cohort ...
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for obesity designed to induce fat burning and preserve muscle mass with once or twice-annual sub...